• OliX Pharmaceuticals' Nov. 10, 2026, correction reports ethics clearance for its New Zealand Phase 2a trial of OLX10212.
• Northern B Health and Disability Ethics Committee reversed its Oct. 12, 2026, rejection following reconsideration.
• The trial targets age-related macular degeneration with bilateral geographic atrophy.
• Trial initiation still requires MedSafe approval; the company plans to disclose that decision upon receipt.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OliX Pharmaceuticals Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261110900550), on November 10, 2026, and is solely responsible for the information contained therein.